South Korea Inhalation Devices Market Overview, 2031

Key Insights

• According to the research report, "South Korea Inhalation Devices Market Outlook, 2031," published by Bonafide Research, the South Korea Inhalation Devices Market is expected to reach a market size of more than 610 Million by 2031.
• The adoption of inhalation devices in South Korea is driven by a rapidly aging society combined with environmental factors such as seasonal yellow dust (Hwangsa) and atmospheric fine particulate matter. According to the Korea Disease Control and Prevention Agency (KDPA) and national health surveys, the prevalence of Chronic Obstructive Pulmonary Disease (COPD) among Korean adults aged 40 and older ranges between 12% and 14%, with rates rising above 30% among seniors aged 70 and older. Additionally, over 2.2 million individuals in South Korea are actively treated for asthma. To manage this burden, the National Health Insurance (NHI) scheme reimburses essential inhalation therapies, creating steady demand for dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and compact nebulizers.
• A major technological breakthrough in South Korea’s respiratory landscape is the rapid integration of Internet-of-Things (IoT) smart inhalers and digital therapeutics (DTx) into tertiary hospital networks. South Korea’s Ministry of Food and Drug Safety (MFDS) has established progressive fast-track approval pathways for software-as-a-medical-device (SaMD) and connected inhaler sensors. Medical centers, such as Seoul National University Hospital and Samsung Medical Center, utilize Bluetooth-connected smart inhaler modules that capture inhalation flow rate, technique accuracy, and dose timing.
• South Korea is witnessing a clinical shift toward Single-Inhaler Triple Therapies (SITT) combining an Inhaled Corticosteroid (ICS), a Long-Acting Beta2-Agonist (LABA), and a Long-Acting Muscarinic Antagonist (LAMA) in a single device. Guided by the Health Insurance Review and Assessment Service (HIRA), Korean pulmonologists increasingly prescribe multi-dose DPI and pMDI combination platforms to streamline complex regimens for elderly patients with co-morbidities.

Market Outlook

• To improve early diagnosis rates and correct inhaler technique in neighborhood clinics, HIRA conducts national "Asthma and COPD Quality Assessment" initiatives that reward primary care physicians for appropriate inhaler prescribing over oral medications. This institutional policy shift is driving volume growth for user-friendly, low-resistance dry powder inhalers, breath-actuated devices, and portable vibrating mesh nebulizers across local outpatient clinics.
• Key organizations establishing clinical protocols and device standards include The Academy of Tuberculosis and Respiratory Diseases (KATRD), The Korean Academy of Asthma, Allergy and Clinical Immunology (KAAACI), the Ministry of Food and Drug Safety (MFDS), and the Health Insurance Review and Assessment Service (HIRA). The commercial device market features prominent domestic pharmaceutical manufacturers alongside major global developers, including Yuhan Corporation, Hanmi Pharmaceutical, Daewoong Pharmaceutical, AstraZeneca Korea, GlaxoSmithKline (GSK) Korea, Boehringer Ingelheim Korea, Chiesi Korea, and Omron Healthcare Korea.

Market Dynamics

Driver: Rapid population aging, environmental factors, and universal NHI support
The primary driver of the South Korean inhalation devices market is the demographic shift toward a super-aged society, compounded by seasonal environmental triggers and universal healthcare coverage. Over 20% of South Korea’s population is aged 65 or older, a demographic highly susceptible to age-related pulmonary decline, Chronic Obstructive Pulmonary Disease (COPD), and asthma. This baseline clinical demand is further exacerbated by environmental stressors, such as seasonal yellow dust (Hwangsa) and fine particulate matter pollution, which frequently trigger severe respiratory exacerbations.
Challenge: Severe tertiary hospital concentration and strict HIRA reimbursement audits
A major operational challenge in South Korea is the extreme concentration of chronic disease care within top-tier university hospitals (tertiary centers), alongside strict reimbursement pricing controls enforced by the Health Insurance Review and Assessment Service (HIRA). Patients in South Korea heavily prefer seeking specialized respiratory treatment at major medical centers in Seoul rather than local primary clinics, creating severe patient bottlenecks and leaving primary care doctors underutilized for routine inhaler management.
Trend: IoT smart inhaler integration with hospital electronic medical records (EMR)
A defining trend reshaping South Korea's respiratory market is the rapid adoption of Internet-of-Things (IoT) smart inhaler technologies and their integration into hospital telehealth platforms. Capitalizing on South Korea's advanced digital health infrastructure and tech-savvy consumer base, medical device developers and pharmaceutical providers are embedding Bluetooth-enabled sensors and electronic dose counters into handheld delivery hardware. Under progressive software-as-a-medical-device (SaMD) regulatory pathways established by the Ministry of Food and Drug Safety (MFDS), these smart modules automatically sync inhalation flow rate, technique accuracy, and dose timing directly to hospital EMR portals.

Segment Analysis

South Korea Inhalation Devices By Product Type
• The South Korea metered dose inhalers market is characterized by the continued role of pressurized devices in delivering portable respiratory treatment and providing options for patients who cannot generate sufficient inspiratory flow for certain alternative inhalers. Spacer compatibility is particularly relevant for children and patients who struggle to coordinate actuation with inhalation. A distinctive market consideration is the need to combine reliable aerosol delivery with simple operating procedures, especially for older patients managing chronic respiratory conditions. Manufacturers can differentiate through consistent dose metering, ergonomic actuators, clear dose counters, and improved compatibility with spacers.
• The South Korea dry powder inhalers market is distinguished by established use in maintenance treatment for asthma and COPD, alongside continuing opportunities for formulation and device innovation. DPIs eliminate the need for propellants and offer portable delivery, but their effectiveness depends on adequate inspiratory effort and correct device preparation. Korean respiratory-care practice places particular emphasis on training patients to load doses correctly, inhale with the required technique, and understand device-specific operating steps. This is especially important for older adults and people with more advanced airflow limitation.
• The South Korea soft mist inhalers market occupies a specialized position by delivering medication as a slowly moving aerosol rather than relying on a conventional propellant-driven spray or patient-powered powder dispersion. This format can reduce coordination demands for some patients and may be suitable for selected maintenance therapies, depending on the prescribed medication and the patient's capabilities. Korean respiratory-care practice recognizes SMIs as one of several inhalation options that should be selected according to clinical circumstances.
• The South Korea nebulizers market is characterized by its role in hospital respiratory care, pediatric treatment, and selected home-care situations where a compatible liquid medication must be aerosolized or a patient cannot use a handheld inhaler effectively. Compressor-based devices offer an established delivery format, while mesh technologies can provide quieter and more compact alternatives depending on the application. A key market consideration is the need to match equipment to the prescribed medication and the patient's ability to maintain the device correctly. Manufacturers can differentiate through dependable aerosol performance, reduced noise, simple assembly, easy cleaning, and accessible replacement components.



South Korea Inhalation Devices By Therapeutic Application
• The South Korea asthma inhalation devices market is shaped by the need for individualized treatment, correct inhaler technique, and consistent use of prescribed controller and reliever medicines. Device selection varies with age, inspiratory capability, hand-breath coordination, and the patient's ability to perform the required operating steps. MDIs with spacers can be appropriate for patients who struggle with coordination, while DPIs and SMIs provide alternatives for suitable individuals. An important market opportunity lies in improving inhalation education through hospitals, outpatient clinics, and community pharmacies, helping patients avoid technique errors that can compromise medication delivery.
• The South Korea COPD inhalation devices market is influenced by the needs of an aging population, the challenges of reduced inspiratory capacity, and the importance of maintaining effective long-term maintenance treatment. Patients may experience difficulties handling devices, coordinating inhalation, or generating sufficient inspiratory flow, making individualized assessment important when choosing between MDIs, DPIs, SMIs, and nebulizers. Korean research on inhaler satisfaction and device-handling errors highlights the importance of considering patient experience alongside clinical suitability. Manufacturers can address these needs through intuitive operating mechanisms, reliable dose delivery, clear instructions, and device designs that reduce avoidable handling errors.
• The others segment of the South Korea inhalation devices market includes applications beyond asthma and COPD, such as bronchiectasis, selected respiratory infections, pulmonary arterial hypertension, and other pulmonary conditions requiring specialized inhaled therapies. These applications may involve medication-specific delivery requirements, complex treatment schedules, or specialist supervision. Nebulizers are relevant for compatible liquid medicines, while specialized handheld inhalers can be used for particular therapies, including selected treatments for pulmonary vascular conditions. South Korea's advanced pharmaceutical and medical-device environment creates opportunities for specialized drug-device development, with an emphasis on reliable aerosol generation and compatibility with specific formulations.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Inhalation Devices Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Metered Dose Inhalers (MDIs)
• Dry Powder Inhalers (DPIs)
• Soft Mist Inhalers (SMIs)
• Nebulizers

By Therapeutic Application
• Asthma
• COPD
• Others